ALK-Abelló upgrades its full-year 2016 financial outlook

4 January 2017

Denmark-based allergy specialist ALK-Abelló (ALKB: DC) has revised its 2016 financial guidance upwards as the company towards the end of 2016 continued to benefit from the temporary and favorable competitive situation in Southern Europe.

The company, whose shares were up 5.57% at 1,004 Danish kroner in trading this morning, says that:

Full-year revenue in the base business is now expected to grow organically by around 25% in local currencies (previously: more than 20%). Fourth-quarter growth is expected at approximately 10% (previously: 'low organic growth').
Total full-year revenue is consequently now estimated at about 3 billion kroner ($425.5 million) compared with the previous forecast of: more than 2.9 billion kroner.
Full-year earnings before interest, taxes, depreciation and amortization (EBITDA) before special items are now expected to be more than 700 million kroner (previously: more than 650 million kroner).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK